Clinical Trials Logo

Filter by:
NCT ID: NCT05996744 Terminated - COVID-19 Clinical Trials

Study of Obeldesivir in Children and Adolescents With COVID-19

Start date: December 26, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19). The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric participants with COVID-19.

NCT ID: NCT05993169 Terminated - Obesity, Morbid Clinical Trials

Body Composition Optimization Intervention RCT

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

This study aims to identify if the addition of structured nutrition/weight loss counseling to patients at the bariatric clinic can increase the conversion from bariatric clinic to surgical candidacy from (the current) 11% to a goal of 20% by way of tracking their BIA measurements.

NCT ID: NCT05984784 Terminated - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Start date: August 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.

NCT ID: NCT05979415 Terminated - Parkinson Disease Clinical Trials

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Start date: September 27, 2023
Phase: Phase 2
Study type: Interventional

This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.

NCT ID: NCT05978063 Terminated - Pruritus Clinical Trials

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Start date: August 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a 2-part, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin for moderate-to-severe pruritus in adult subjects with NP.

NCT ID: NCT05962710 Terminated - Diabetes Mellitus Clinical Trials

FreeStyle Libre 3 Continuous Glucose Monitoring System

Start date: January 27, 2023
Phase:
Study type: Observational

The purpose of this study is to characterize the FreeStyle Libre 3 Continuous Glucose Monitoring System performance with respect to YSI reference venous plasma sample measurements.

NCT ID: NCT05961046 Terminated - Cataract Clinical Trials

Visual Performance of the Vivity IOL in Post-myopic LASIK and PRK Patients

Start date: August 17, 2023
Phase:
Study type: Observational

The objective is to evaluate visual outcomes and patient satisfaction in patients with a history of myopic LASIK or PRK who will have completed cataract surgery with the Vivity IOL.

NCT ID: NCT05956496 Terminated - Gingival Recession Clinical Trials

Gingival Augmentation and Root Coverage With Superficial and Deep Cut Acellular Dermal Matrices

Start date: October 3, 2023
Phase: N/A
Study type: Interventional

This entire protocol involves procedures that are standard care and will randomize subjects to of one two routine care procedures. Patients needing root coverage for gingival recession will be enrolled.

NCT ID: NCT05954052 Terminated - Clinical trials for Autism Spectrum Disorder

A Study of Glutathione in Children With Autism Spectrum Disorder

Start date: July 1, 2019
Phase: Phase 4
Study type: Interventional

The aim of this study is to investigate if taking a supplement called Glutathione by mouth is safe and practical for children and teenagers with Autism Spectrum Disorder (ASD). The researchers plan to involve 24 individuals with ASD and give them oral Glutathione for 12 weeks.

NCT ID: NCT05943990 Terminated - Neoplasms Clinical Trials

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Start date: December 21, 2020
Phase: Phase 1
Study type: Interventional

To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of GSK3845097 in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive participants with New York esophageal squamous cell carcinoma (NY-ESO)-1 and/or Cancer testis antigen 2 (LAGE-1a) positive, previously treated, advanced (metastatic or unresectable) Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCLS).